Search Results

LifeTech Scientific Corporation, a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries announced the audited consolidated results for the year ended 31 December 2023.

AUM LifeTech, Inc. announced a collaboration with Colorado State University (CSU) on a DARPA-funded project using AUM LifeTech’s self-deliverable RNA Silencing FANA Antisense Oligonucleotides (FANA ASO) technology.

AUM LifeTech, Inc., a Philadelphia-based preclinical stage biotechnology company, has received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to advance their preclinical program in lung cancer immunotherapy using a non-viral RNA-targeting gene therapy approach.

LifeTech Scientific Corporation announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended 30 June 2023.

AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on discovering and developing precision oncology therapeutics, announced today that the first patient has been dosed in its Phase 2 clinical trial evaluating AUM001 for the treatment of metastatic colorectal cancer (MSS CRC).

AUM LifeTech, Inc., a preclinical stage biotechnology company, announced today that it has been selected by the National Institutes of Health (NIH) to present an update on their drug development pipeline at 2021 BIO Digital, the premier biotech event

AUM Biosciences Pte. Ltd. announced that the management team will participate in the Inaugural EF Hutton Global Conference in New York, New York from May 10th to May 11th.

AUM Biosciences Pte. Ltd. announced that the U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation for its product candidate, AUM302, a potential first-in-class oral kinase inhibitor that targets not only PI3K, but also key resistance mechanisms such as PIM and mTOR, for the treatment of neuroblastoma.

LifeTech Scientific Corporation, a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, announced its 2022 annual results.

AUM Biosciences Pte. Ltd. (“AUM”) announced today that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation for AUM302, a potential first-in-class oral kinase inhibitor that targets not only PI3K, but also key resistance mechanisms such as PIM and mTOR, for the treatment of neuroblastoma.